RNS Number : 5246D
GlaxoSmithKline PLC
19 February 2020
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO of ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Following the vesting on 16 February 2020 of 25% of an award made on 16 February 2015 under the GlaxoSmithKline Deferred Investment Award programme, Ms Waterhouse will receive a cash payment of £240,634.43 less applicable tax withholding in respect of 14,421.337 notional Ordinary Shares.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£16.686

14,421.337

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2020-02-16

f)

Place of the transaction

 

N/A

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDKLFFBLLLBBL